AI Science Tracker

Automated methylome analysis identified candidate blood epigenetic markers for first-episode schizophrenia

Democritus University of Thrace; Aristotle University of Thessaloniki; University of Crete; Hellenic Mediterranean University; Foundation for Research and Technology – Hellas · 17 Jun 2024 · medicine

Discovery

Automated methylome analysis identified candidate blood epigenetic markers for first-episode schizophrenia

An automated machine-learning workflow screened public blood-methylation datasets and selected IGF2BP1, CENPI and PSME4 as candidate schizophrenia-associated methylation markers. The researchers then measured these genes by targeted qMSP in 30 first-episode, drug-naive schizophrenia patients and 30 controls: IGF2BP1 methylation was higher and PSME4 lower in cases, while CENPI did not differ. A five-feature model combining the three genes with age and sex classified cases versus controls with AUC 0.755 (95% CI 0.636–0.862).

Technology: JADBio AutoML platform, comparing classifiers including support-vector machines, random forests, ridge logistic regression and decision trees with feature selection and cross-validation

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: direct test
  • Tested: The researchers then measured these genes by targeted qMSP in 30 first-episode, drug-naive schizophrenia patients and 30 controls: IGF2BP1 methylation was higher and PSME4 lower in cases, while CENPI did not differ.
  • Still unknown: The patient validation was a small case-control pilot (30 first-episode cases and 30 healthy controls); its AUC of 0.755 is modest and has a wide confidence interval. CENPI methylation did not differ in the clinical samples, so it should not be presented as independently validated. The study does not establish diagnostic performance in clinical differential-diagnosis populations, prospective utility or causality, and the authors describe the signature as potentially useful for future diagnostics rather than clinically established.
  • AI role: AutoML selected gene-methylation features from genome-wide public schizophrenia methylome datasets and built predictive signatures. The authors then measured the selected markers using qMSP in a separate 30-case/30-control first-episode drug-naive cohort and trained a second model on methylation plus demographic variables.

Evidence sources: https://www.nature.com/articles/s41398-024-02946-4.pdf

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review scope and date are not recorded; source checked does not establish full-text review.

Citations: at percentile 78 of works of the same type, year and subfield (OpenAlex work metrics, 12 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.

Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Open in the full catalog for filters, charts and related discoveries.